Apigenin Regulating PI3K/AKT Pathway to Improve Depressive Behavior in Epileptic Rats

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Epilepsy frequently co-occurs with depression, diminishing patient quality of life.
• The hippocampus is vulnerable in epilepsy and implicated in depression and neurodegeneration.
• Epileptogenesis involves inflammation, oxidative stress, and neuronal damage, with the PI3K/AKT pathway being crucial.

Purpose of the Study:

• Investigate the therapeutic mechanisms of Apigenin (API) in a rat model of epilepsy-induced depression.
• Focus on API's effects on hippocampal neurogenesis and the PI3K/AKT signaling pathway.
• Evaluate API's potential as an anti-epileptic and antidepressant agent.

Main Methods:

• Induced epilepsy and depression in rats using Lithium chloride (LiCl) and pilocarpine.
• Administered API and valproate (VPA) to assess effects on depressive behavior and astrocytes.
• Utilized network pharmacology to predict API's molecular targets for epilepsy.
• Performed in vivo experiments to validate the predicted mechanisms.

Main Results:

• API and VPA significantly reduced seizure frequency, severity, and depressive behaviors.
• Histological analysis revealed API and VPA mitigated neuronal damage (nuclear contraction, cell swelling) and improved hippocampal structure (Nissl bodies).
• API and VPA reversed changes in the PI3K/AKT pathway signaling and reduced glial fibrillary acidic protein (GFAP) expression, indicating suppressed astrocyte activation.

Conclusions:

• Apigenin (API) demonstrates anti-epileptic and antidepressant effects in a rat model, comparable to valproate (VPA).
• API mitigates hippocampal neuronal damage and suppresses astrocyte activation, likely through modulating the PI3K/AKT pathway.
• API shows promise as a neuroprotective agent for epilepsy and comorbid depression, warranting further investigation into its direct PI3K/AKT pathway interactions.